#China plans to enforce real names on Social media Chinese government has issued new regulations to eliminate fake social media accounts.
Thanks to this, the article published today in PLOS ONE describes a new step towards the creation of a vaccine,
This technique could be a much better candidate for a human vaccine. The invention is protected commercially
and to cure the disease by combining the vaccine with regenerative therapies. The Germans Trias Institute plans to carry out these steps with patients at the hospital
which is why the chances of developing an effective vaccine have been deemed low.)They show that this new formulation reduces the minimal curative dose in a disease model, based on infections in mice, by 100-fold and,
""The hope for a definitive cure and an effective vaccine has been frustrated by HIV's endless propensity to subvert the host's defences
#MERS Not Given Same Vaccine Attention as Ebola, Other Viruses A MERS outbreak has infected about 150 people in South korea,
But a vaccine is not among their tools since it doesn yet exist, and is probably not close to being developed.
has no vaccine, according to the Centers for Disease Control and Prevention. MERS was discovered only in 2012 in Saudi arabia.
However, fewer companies have worked on vaccines and drugs for the MERS virus, according to Reuters. Small biotech companies such as Greffex,
Inovio and Novavax have done all some investigation on vaccines for the sickness but the research is still all preclinical,
Ebola research, including vaccines and treatments, dominated headlines worldwide in the wake of the outbreak of the virus in multiple West african nations last year.
000 doses of its Phase I trial vaccine in Africa. However, other viruses were also acingfor deployment amid the panicked fears as that outbreak spread.
The SARS vaccine work proceeded for years but since the virus mostly disappeared, there are not enough live examples of disease to effectively test it, according to multiple reports.
#Could Dissolvable Microneedles Replace Injected Vaccines? Osaka University Study Eric is terrified. He stands outside the clinic and takes a few deep breaths before walking slowly through the automatic doors.
A new vaccine delivery system could solve this problem: dissolvable microneedle patches are simple to use, pain-free and effective.
Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine,
Downsizing to address the needle problem Most vaccines are injected under the skin or into the muscle using needles.
taking the vaccine with them. The researchers compared the new system to traditional needle delivery by vaccinating two groups of people against three strains of influenza:
A/H1n1, A/H3n2 and B. None of the subjects had a bad reaction to the vaccine,
people given the vaccine using the microneedles had an immune reaction that was equal to or stronger than those given the vaccine by injection. e were excited to see that our new microneedle patch is
just as effective as the needle-delivered flu vaccines, and in some cases even more effective, said Dr. Nakagawa. e have shown that the patch is safe and that it works well.
Since it is also painless and very easy for non-trained people to use, we think it could bring about a major change in the way we administer vaccines globally.
New approaches to vaccination According to the World health organization immunization prevents an estimated 2 million to 3 million deaths every year.
The continued threat of pandemics such as H1n1 swine flu and emerging infectious diseases such as Ebola makes vaccine development and mass vaccination a priority for global healthcare.
Delivery methods that do not require needles are safer for the person administering the vaccine,
more pleasant for the person receiving the vaccine, and potentially less expensive. The challenge is developing a delivery method that gets the vaccine into the body effectively.
Microneedles provide one such delivery method, and they can be made of various different materials. Previous research has evaluated the use of microneedles made of silicon or metal
For some diseases, vaccines may be more effective when theye absorbed through the mucous membranes in the nose.
For example, studies in mice have suggested that tuberculosis vaccines delivered through the noseare more effective than those that are injected,
either alone or as an adjunct to traditional parenteral methods of vaccine administration. e
#Bionic Hand Uses Smart Wires To Mimic Muscle fibers, Study Engineers in Germany have built a biologically inspired artificial hand with muscles made from bundles of'smart'wires.
A single vaccine that immunizes against all types of influenza may soon be a reality,
Researchers said that the breakthrough could lead to the development of a vaccine that can fight all new influenza viruses. Professor Xu,
China, said this study would significantly enlighten T-cell based vaccine development and immune intervention during severe influenza infection in the future.
Vaccination will no longer be a painful process as researchers from Japan's Osaka University have developed a new technique that can deliver vaccines without needles.
Vaccination will no longer be a painful process as researchers from Japan's Osaka University have developed a new technique that can deliver vaccines without needles.
Through this technology, vaccines are delivered simply by laying a tiny patch onto a person's finger,
just as effective as the needle-delivered flu vaccines, and in some cases even more effective,"said Professor Nakagawa, one of the authors of the Osaka University study.
#Approval for AIDS Vaccine at Canadian University The Food and Drug Administration has given Canadian researchers approval to test a vaccine for HIV/AIDS on humans.
a vaccine could be on the market in about five years. Similar to the approaches used to develop vaccines for polio, influenza, rabies and Hepatitis a,
the vaccine is the first based on a genetically modified, killed whole virus and is the only HIV vaccine currently under development in Canada,
and one of the only few in the world. Beginning next month a clinical trial on 40 HIV-positive volunteers will begin.
Following the trials, tests will begin on 6, 600 HIV-negative but high-risk category volunteers.
These tests will focus on immune responses and effectiveness of the vaccine in two more phases s
The flu vaccine isn perfect, though. Influenza mutates rapidly, which means a new vaccine formulation is needed every year.
An international team of researchers has identified a new antibody that might give us the edge in this yearly arms race.
A vaccine provides a template of antigens to train the immune response to recognize the new strains of influenza each year.
Doctors have to predict which strains will be most prevalent in the upcoming flu season to formulate the vaccine
which will go a long way toward clearing the virus. She also believes HIV vaccines in development could give patients an extra edge.
Even a vaccine that isn 100 percent effective at preventing transmission could boost a patient ability to destroy reactivated virus. However,
and there currently is no treatment or vaccine. We continue to study the virus to improve our understanding of how it works
#Dissolvable Microneedles May Herald New Age of Vaccine Delivery Scientists from Osaka University report that flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine.
The continued threat of pandemics such as H1n1 swine flu and emerging infectious diseases such as Ebola makes vaccine development and mass vaccination a priority for global healthcare.
Most vaccines are injected under the skin or into the muscle using needles. While this is an effective delivery method,
taking the vaccine with them. The researchers compared the new system to traditional needle delivery by vaccinating two groups of people against three strains of influenza:
and B. None of the subjects had a bad reaction to the vaccine, showing that it is safe to use in humans.
people given the vaccine using the microneedles had an immune reaction that was equal to or stronger than those given the vaccine by injection."
just as effective as the needle-delivered flu vaccines, and in some cases even more effective,"said Dr. Nakagawa.
we think it could bring about a major change in the way we administer vaccines globally, "said Dr. Nakagawa a
#Biopharma Demand Is Driving the Cell Culture Market The production of biologic therapies such as vaccines, blood factors,
Market Drivers An important driver of the cell culture market is the production of seasonal influenza vaccines,
as well as pandemic vaccine candidates. Seasonal influenza vaccines have traditionally been produced using egg-based technology. However, this labor-intensive approach to vaccine development is currently being replaced by cell-culture systems.
Prefluce, the first cell culture-based vaccine, received European approval in March 2011 and was available for the 2011012 influenza season in the 13 participating European union countries.
On November 20 2012, the U s. Food and Drug Administration approved the use of Flucelvax, which is the first U s.-licensed (trivalent inactivated) influenza vaccine manufactured using cell culture technology.
Stem cell research will also add to the robust growth of the cell culture market. The growing use
and diverse applications of stem cells are having a significant impact on the media market,
#Merck-Newlink Genetics Ebola Vaccine Shows 100%Efficacy in Phase III Trial Merck & co. and Newlink Genetics said today that a single dose of their Ebola vaccine candidate rvsv
According to those findings, all individuals who received the vaccine were protected against Ebola virus infection within 6 to 10 days of vaccination. he results of this interim analysis indicate that rvsv-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease
showing a vaccine efficacy of 100%,the researchers added. The international team carrying out the trial included researchers from the World health organization, the Norwegian Institute of Public health, the Health Ministry of Guinea,
and Médecins sans Frontières. he extraordinary efforts of the team in Guinea and other experts have yielded interim results that suggest a potential role for our rvsv-ZEBOV vaccine in the fight against Ebola disease, Roger
e hope that the interim data published today contribute to the successful registration of our vaccine candidate,
The Sierra leone Trial to Introduce a Vaccine against Ebola (STRIVE) Phase III study being conducted by the Sierra leone College of Medicine and Allied Health Sciences, Sierra leone Ministry of Health,
The Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase II study being conducted by a Liberia-NIH partnership in Liberia.
To date, the rvsv-ZEBOV vaccine has been administered to more than 9, 000 people in Phase I, II,
To produce the vaccine, the vesicular stomatitis virus was weakened by removing a gene and replacing it with a single Ebola virus gene that alone cannot cause the disease.
Newlink also said it was tiered eligible for royalties on sales of the vaccine n certain markets, subject to certain conditions.
Major funding for these studies has come from sources that include the U s. Department of defense Defense Threat Reduction Agency and Joint Vaccine Acquisition Program, the U s. Department of health and Human Service Biomedical Advanced Research Development Authority,
and research related to the Ebola vaccine candidate, but primarily due to clinical trial expenses related to its pipeline of product candidates, including its Hyperacute immunotherapy cancer programs and its IDO pathway inhibitor (indoximod) programs
or READ more at Daily mail) Pass on the Good Newsbelow) TAGSBREAKTHROUGHHEALTHINNOVATIONMEDICALSCIENCEWELLNESS Cuban Cancer Vaccine Could Soon be Available in U s. May 20,
#World First Malaria Vaccine Approved and it Will be Not-for-Profit The world first malaria vaccine has been given approval by a European medical agency for future use in Sub-saharan africa, where more than a quarter million children under the age of five die every year from the disease.
European regulators examined phase III clinical trial results involving more than 16,000 young children conducted by research centers in eight African countries (Burkina faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria
Glaxosmithkline Vice president for Africa told CNN. t is the first time anyone ever has been able to make a vaccine against a parasite.
Perhaps most impressive, Glaxosmithkline, the pharmaceutical company that worked on this vaccine for 30 years, and received $200 million from the Gates Foundation, is making RTS, S available as a nonprofit drug.
with all that money going back into further research for a malaria vaccine that could be even more effective.
and expects to invest a further $200 to $250 million until the vaccine is ready for market.
With this approval from the European Medicines Agency Friday, the vaccine next will be considered by the World health organizations,
and if they will use the vaccine, along with current Malaria prevention techniques, like bed nets. 80%of the children involved in the clinical trials were protected also by insecticide treated bed nets.
Administering a vaccine to protect against infection would overwhelm the patient's immune system. However, if he or she has the option of receiving an antiviral to eliminate the infection,
News and information A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015discoveries A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015announcements A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015interviews/Book reviews/Essays/Reports/Podcasts/Journals/White papers A step towards a type 1 diabetes vaccine by using nanotherapy June 10th,
#Freshly squeezed vaccines (Nanowerk News) MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune systems B cells,
and implementing antigen-presenting cell vaccines. Such vaccines, created by reprogramming a patients own immune cells to fight invaders,
hold great promise for treating cancer and other diseases. However, several inefficiencies have limited their translation to the clinic,
While most of these vaccines are created with dendritic cells, a class of antigen-presenting cells with broad functionality in the immune system,
A new vaccine-preparation approach Dendritic cells are the most naturally versatile antigen-presenting cells.
when for cell-based vaccines: They have a short lifespan, they do not divide when activated,
which has limited options for B-cell-based vaccine programming. Using Cellsqueeze circumvents this problem and by being able to separately configure delivery and activation,
researchers have greater control over vaccine design. Gail Bishop, a professor of microbiology at the University of Iowa Carver School of medicine and director of the schools Center for Immunology and Immune-Based Diseases, says that this paper presents a creative new approach with considerable
potential in the development of antigen-presenting cell vaccines. The antigen-presenting capabilities of B cells have often been underestimated,
in this new study, demonstrates promise as a versatile platform for creating more effective cell-based vaccines.
Future steps The researchers say they now plan to refine their B-cell-based vaccine to optimize distribution and function of the immune cells in the body.
A b-cell-based approach could also reduce the amount of patient blood required to prepare a vaccine.
patients receiving cell-based vaccines must have drawn blood over several hours each time a new dose must be prepared.
and cost required to engineer cell-based vaccines. We envision a future system, if we can take advantage of its microfluidic nature,
and then youd have the vaccine, Szeto says s
#Nanotechnology helps protect patients from bone infection Leading scientists at the University of Sheffield have discovered nanotechnology could hold the key to preventing deep bone infections,
as guinea pigsvicious vaccine culture war now being waged against informed, intelligent Americans who seek to protect their children from deadly side effects131 Ways for an Infant to Die:
Vaccines and Sudden Deathnaturalnews exclusive: Michigan government unleashes armed raids on small pig farmers, forces farmer to shoot all his own pigs/**CONFIGURATION VARIABLES:
as a result of an infection and those triggered by a vaccine. Instead the technique might be useful in outbreaks of new viruses. Understanding how our immune system responds to other viral fragments might reveal clues as to
rumours the vaccine was contaminated with HIV and violence nine health workers were killed by terrorist group Boko Haram in 2013.
#Ebola Vaccine Hailed As'Game Changer'In Fight Against The Virus Doctors Without Borders is calling it a"champagne moment."
"In a small trial, an experimental vaccine protected 100 percent of participants who were at high risk for the virus
vaccine or medicine,"says Dr. Marie-Paule Kieny, assistant director-general for health systems and innovation at the World health organization,
"The vaccine, called rvsv-ZEBOV, was developed by the Public health Agency of Canada. Previous studies showed it was safe.
The vaccine stops Ebola in its tracks, Kieny says.""When we talked with our colleagues who are responding to Ebola cases,
now that Kieny and her team couldn't use the standard method for testing a vaccine.
When a case crops up, the team rushes to scene andgives the vaccine to people who are close to the sick person those who are at high risk of getting the virus."So this can be the neighbors, the family, the coworkers,
In the group that got the vaccine immediately, no one got Ebola.""No cases at all. Zero,"Kieny says."
The problem is there were only 16 cases of Ebola in the group that didn't get the vaccine immediately.
That's way too small of a number to say how well the vaccine works,
But statistical analyses suggest the vaccine's efficacy is at least 70 percent, Kieny says which is still good enough to stop the spread of the disease."
preliminary results of this vaccine trial from Guinea,"says Dr. Jesse Goodman, an infectious disease specialist at Georgetown University, who once led vaccine development at the U s. Food and Drug Administration.
More data are needed to nail down the vaccine's efficacy. And there were a few issues with the design of the experiment that could have skewed the results."
and late suggests strongly to me that this vaccine is working. i
#The Future Of Cardiology Will be shown In 3-D How can you tell the difference between a good surgeon and an exceptional one?
#Highly-Effective Ebola Vaccine Could Stymie Future Outbreaks Over 27,000 cases and 11561 deaths. The statistics that tell the story of the most recent Ebola outbreak are stark,
That the conclusion of a study on an Ebola vaccine developed in a 10-month sprint by the Public health Agency of Canada
000 individuals in Guinea, are welcome news. Kimberley Steeds, an Ebola vaccine trial team member, in the Ebola vaccine laboratory, Donka Hospital in Conakry,
The vaccine is consists of a modified version of a different virus called VSV, which infects cows
The new study evaluated the vaccine effectiveness by dividing recipients into two randomly assigned groups.
Half of the study participants received the vaccine as soon as one person they had been in contact withhether it was a relative, patient,
The other half received the vaccine after a delay of three weeks. In the 2, 000 subjects receiving the immediate vaccination treatment, not one person contracted Ebola.
Even with the vaccine apparent efficacy, the trial will continue so researchers can gather more information to license the vaccine for widespread use.
The sheer scale of the 2014-15 outbreak led to an unprecedented push on vaccines and a decade work has been condensed into around 10 months.
but the vaccine trials offer, for the first time, hope that such grim statistics will never be seen again n
Flu vaccines effectively give your immune system a antedposter based on researchersbest predictions for the mutation that year.
This work suggests that future flu vaccines could include this new kind of antibody that would be able to fight the most powerful types of influenza viruses
That might make for stronger flu vaccines --and possibly reduce the shot's frequency to once every few years e
#New Ebola Vaccine Shows 100 Percent Effectiveness In Early Tests At this time last summer, the horrific and often fatal disease Ebola was ravaging West Africa in the deadliest outbreak
But in an extremely promising medical advance, scientists are now saying that an experimental Ebola vaccine with 100 percent effectiveness has been developed.
A paper published today in The british medical journal Lancet reports that the vaccine which has been tested in Guinea
what known as a ing vaccination strategyto test the vaccine efficacy. This involves inoculating all known contacts of an infected individual,
more conclusive evidence is necessary to prove the vaccine ability to protect larger populations from the disease, according to THE WHO. This trait,
known as erd immunity, is especially vital in order for the vaccine to be truly successful. The trial faced some obstacles in the beginning,
because volunteers knew they were receiving the actual vaccine. This raised a number of questions on ethical and scientific grounds,
It is expected that this vaccine will likely be used to stop future outbreaks rather than vaccinate whole populations.
The speed and efficiency with which this vaccine was developed and tested in the midst of a global medical emergency is unparalleled.
particularly those that store vaccines and other medical products. Published in The Lancet. This study was funded by a gift from the Abundance Foundation (Stephen Kahn.
#Toward A Universal Flu Vaccine Flu vaccines can be shot a in the dark-they must be given yearly
New research suggests it may be possible to harness a previously unknown mechanism within the immune system to create more effective and efficient vaccines against this ever-mutating virus. In a Cell paper,
"While the conventional flu vaccine protects only against specific strains, usually three of them, our experiments show that by including modified antibodies within the vaccine it may be possible to elicit broad protection against many strains simultaneously,
"says senior study author Jeffrey Ravetch, professor of Molecular genetics and Immunology at Rockefeller University.""We believe these results may represent a preliminary step toward a universal flu vaccine,
one that is effective against a broad range of the flu viruses."It was known already that chemical modifications to antibodies'Fc region altered their interactions with immune cells,
The virus makes for a difficult target for vaccines because its strains are so diverse,
most flu vaccines in the United states are formulated to target a total of three or four viral strains:
A universal flu vaccine has become something of a holy grail, and a number of strategies have been proposed to create it.
These regions go on form complexes with vaccine antigens, which then modulate the evolving vaccine response.
First, the researchers vaccinated healthy volunteers with a seasonal flu vaccine containing an inactivated strain of the H1n1 virus. They then tracked the volunteers'immune responses via blood samples,
keeping an eye out for chemical modifications to antibodies against the hemagglutinin protein. About seven days after the vaccination, they saw a spike in sialylated antibodies, meaning sialic acid,
the better a person's response to the vaccine. To tease apart how this chemical modification improves the immune response,
The result of the higher affinity was broad protection against H1 subtype influenza viruses. The researchers then used this knowledge to improve the vaccine itself.
They modified the H1n1 vaccine so it contained not only protein from the virus itself, but also sialylated antibodies against that protein."
which a vaccine containing sialylated antibodies elicits broadly protective antibodies, could potentially be harnessed to reduce the tremendous morbidity
"We are now looking into applying this strategy toward improving existing vaccines; ideally, this would result in a vaccine that provides life long immunity against flu infections. s
#Human Antibody Blocks Dengue virus In Mice Researchers have discovered that a human antibody specific to dengue virus serotype 2,
--and they suggest that the site where 2d22 binds to the virus could represent a potential vaccine target.
and there is currently no protective vaccine available. Recent phase 3 clinical trials of a potential vaccine candidate showed poor efficacy,
especially against dengue virus serotype 2. Guntur Fibriansah and colleagues found that 2d22 protects mice against dengue virus serotype 2,
Vaccines and health clinics can be up and running earlier and any necessary travelling restrictions can be put in place before the situation worsens."
#New Ebola vaccine is 100%successful in Guinea clinical trials A new single-dose vaccine has been shown to be 100 percent effective against Ebola after just one week.
Known as VSV-ZEBOV, the vaccine is now going through further trials in younger patients, and if all goes to plan could become the first licensed vaccine against Ebola.
As of right now around 28,000 people in Guinea, Sierra leone and Libera have been infected with Ebola,
A second study group of 3, 528 people were injected with the vaccine three weeks after they'd potentially been exposed to Ebola.
"The initial results of the study show that the vaccine can effectively contain the further spread of the Ebola virus,"the University of Bern in Switzerland,
"We believe that the world is on the verge of an efficacious Ebola vaccine, "World Health Organisation (WHO) vaccine expert Marie Paule Kieny told reporters at a media briefing announcing the results on Friday.
The trial, which was supported by the drug firm Merck, THE WHO and the Canadian, Norwegian and Guinean governments, is now continuing in children between the ages of 13 and 17.
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011